{"pmid":32314081,"title":"Pharmacologic Therapy for COVID-19 Infection.","text":["Pharmacologic Therapy for COVID-19 Infection.","The COVID-19 pandemic has focused attention on issues of epidemiology, public health, and vaccine design. I submit that attention to COVID-19 pharmacologic therapy needs similar emphasis, including identifying any existing medications that can be repurposed to treat COVID-19 patients.","J Community Health","Nusbaum, Neil","32314081"],"abstract":["The COVID-19 pandemic has focused attention on issues of epidemiology, public health, and vaccine design. I submit that attention to COVID-19 pharmacologic therapy needs similar emphasis, including identifying any existing medications that can be repurposed to treat COVID-19 patients."],"journal":"J Community Health","authors":["Nusbaum, Neil"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32314081","week":"202017|Apr 20 - Apr 26","doi":"10.1007/s10900-020-00821-z","keywords":["antiviral therapy","covid-19","case control studies"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664714520036114432,"score":8.518259,"similar":[{"pmid":32329520,"title":"Current pharmacological treatments for COVID-19: what's next?","text":["Current pharmacological treatments for COVID-19: what's next?","Starting from December 2019 the novel SARS-Cov-2 has spread all over the world, being recognized as the causing agent of COVID-19. Since nowadays no specific drug therapies neither vaccines are available for the treatment of COVID-19, drug repositioning may offer a strategy to efficiently control the clinical course of the disease and the spread of the outbreak. In this paper we aim to describe the main pharmacological properties, including data on mechanism of action, safety concerns and drug-drug interactions, of drugs currently administered in patients with COVID-19, focusing on antivirals and drugs with immune-modulatory and/or anti-inflammatory properties. Where available, data from clinical trials involving patients with COVID-19 were reported. Several studies have been registered worldwide and a number of drugs were repurposed to face the new health emergency of COVID-19. For many of these drugs, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab, preliminary clinical trials seem to support their benefit in improving patients' clinical conditions. However, adequate clinical trials are necessary to reach any firm conclusion on the efficacy and safety profiles of these compounds. Even though drug repurposing is necessary, it requires caution. Too many drugs that are currently tested in patients with COVID-19 have peculiar safety profiles. In conclusion, while waiting for the development of effective preventive measures, such as vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. It is conceivable that very soon their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications.","Br J Pharmacol","Scavone, Cristina","Brusco, Simona","Bertini, Michele","Sportiello, Liberata","Rafaniello, Concetta","Zoccoli, Alice","Berrino, Liberato","Racagni, Giorgio","Rossi, Francesco","Capuano, Annalisa","32329520"],"abstract":["Starting from December 2019 the novel SARS-Cov-2 has spread all over the world, being recognized as the causing agent of COVID-19. Since nowadays no specific drug therapies neither vaccines are available for the treatment of COVID-19, drug repositioning may offer a strategy to efficiently control the clinical course of the disease and the spread of the outbreak. In this paper we aim to describe the main pharmacological properties, including data on mechanism of action, safety concerns and drug-drug interactions, of drugs currently administered in patients with COVID-19, focusing on antivirals and drugs with immune-modulatory and/or anti-inflammatory properties. Where available, data from clinical trials involving patients with COVID-19 were reported. Several studies have been registered worldwide and a number of drugs were repurposed to face the new health emergency of COVID-19. For many of these drugs, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab, preliminary clinical trials seem to support their benefit in improving patients' clinical conditions. However, adequate clinical trials are necessary to reach any firm conclusion on the efficacy and safety profiles of these compounds. Even though drug repurposing is necessary, it requires caution. Too many drugs that are currently tested in patients with COVID-19 have peculiar safety profiles. In conclusion, while waiting for the development of effective preventive measures, such as vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. It is conceivable that very soon their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications."],"journal":"Br J Pharmacol","authors":["Scavone, Cristina","Brusco, Simona","Bertini, Michele","Sportiello, Liberata","Rafaniello, Concetta","Zoccoli, Alice","Berrino, Liberato","Racagni, Giorgio","Rossi, Francesco","Capuano, Annalisa"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329520","week":"202017|Apr 20 - Apr 26","doi":"10.1111/bph.15072","keywords":["covid-19","anti-inflammatory agents","antivirals","clinical practice","clinical research","immuno-modulatory agents","literature review","pharmacological treatments"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["favipiravir","lopinavir-ritonavir drug combination","tocilizumab","remdesivir"],"_version_":1664996914811109377,"score":151.27591},{"pmid":32040667,"pmcid":"PMC7079862","title":"Critical care management of adults with community-acquired severe respiratory viral infection.","text":["Critical care management of adults with community-acquired severe respiratory viral infection.","With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17-53% of such patients. In addition, novel pathogens including zoonotic coronaviruses like the agents causing Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and the 2019 novel coronavirus (2019 nCoV) are still being identified. Patients with severe RVIs requiring ICU care present typically with hypoxemic respiratory failure. Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza. At present, there are no antiviral therapies of proven efficacy for other severe RVIs. Several adjunctive pharmacologic interventions have been studied for their immunomodulatory effects, including macrolides, corticosteroids, cyclooxygenase-2 inhibitors, sirolimus, statins, anti-influenza immune plasma, and vitamin C, but none is recommended at present in severe RVIs. Evidence-based supportive care is the mainstay for management of severe respiratory viral infection. Non-invasive ventilation in patients with severe RVI causing acute hypoxemic respiratory failure and pneumonia is associated with a high likelihood of transition to invasive ventilation. Limited existing knowledge highlights the need for data regarding supportive care and adjunctive pharmacologic therapy that is specific for critically ill patients with severe RVI. There is a need for more pragmatic and efficient designs to test different therapeutics both individually and in combination.","Intensive Care Med","Arabi, Yaseen M","Fowler, Robert","Hayden, Frederick G","32040667"],"abstract":["With the expanding use of molecular assays, viral pathogens are increasingly recognized among critically ill adult patients with community-acquired severe respiratory illness; studies have detected respiratory viral infections (RVIs) in 17-53% of such patients. In addition, novel pathogens including zoonotic coronaviruses like the agents causing Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS) and the 2019 novel coronavirus (2019 nCoV) are still being identified. Patients with severe RVIs requiring ICU care present typically with hypoxemic respiratory failure. Oseltamivir is the most widely used neuraminidase inhibitor for treatment of influenza; data suggest that early use is associated with reduced mortality in critically ill patients with influenza. At present, there are no antiviral therapies of proven efficacy for other severe RVIs. Several adjunctive pharmacologic interventions have been studied for their immunomodulatory effects, including macrolides, corticosteroids, cyclooxygenase-2 inhibitors, sirolimus, statins, anti-influenza immune plasma, and vitamin C, but none is recommended at present in severe RVIs. Evidence-based supportive care is the mainstay for management of severe respiratory viral infection. Non-invasive ventilation in patients with severe RVI causing acute hypoxemic respiratory failure and pneumonia is associated with a high likelihood of transition to invasive ventilation. Limited existing knowledge highlights the need for data regarding supportive care and adjunctive pharmacologic therapy that is specific for critically ill patients with severe RVI. There is a need for more pragmatic and efficient designs to test different therapeutics both individually and in combination."],"journal":"Intensive Care Med","authors":["Arabi, Yaseen M","Fowler, Robert","Hayden, Frederick G"],"date":"2020-02-11T11:00:00Z","year":2020,"_id":"32040667","week":"20207|Feb 10 - Feb 16","doi":"10.1007/s00134-020-05943-5","keywords":["acute respiratory distress syndrome","antiviral therapy","coronavirus","influenza","neuraminidase inhibitor"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Ascorbic Acid","Macrolides","Sirolimus","Oseltamivir"],"_version_":1664640875328700417,"score":127.75768},{"pmid":32335281,"title":"Pharmacologic perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19.","text":["Pharmacologic perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19.","Coronavirus disease 2019 (COVID-19) caused by a previously unknown pathogen named severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has now become a pandemic threat to the whole world. However, there are no vaccines or specific treatment against the new virus. Therefore, there is an urgent need for advancing novel therapeutic interventions for COVID-19. Glycyrrhizin, a triterpene saponine, is valuable for its various biological functions and pharmacology effects. In this brief article, we will discuss the therapeutic potential of glycyrrhizin for COVID-19 from the perspective of its pharmacological action including binding angiotensin converting enzyme II (ACE2), down-regulating proinflammatory cytokines, inhibiting the accumulation of intracellular ROS, inhibiting thrombin, inhibiting the hyperproduction of airway exudates, and inducing endogenous interferon.","Int J Antimicrob Agents","LuoLiu, PanDong","Li, Juan","32335281"],"abstract":["Coronavirus disease 2019 (COVID-19) caused by a previously unknown pathogen named severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has now become a pandemic threat to the whole world. However, there are no vaccines or specific treatment against the new virus. Therefore, there is an urgent need for advancing novel therapeutic interventions for COVID-19. Glycyrrhizin, a triterpene saponine, is valuable for its various biological functions and pharmacology effects. In this brief article, we will discuss the therapeutic potential of glycyrrhizin for COVID-19 from the perspective of its pharmacological action including binding angiotensin converting enzyme II (ACE2), down-regulating proinflammatory cytokines, inhibiting the accumulation of intracellular ROS, inhibiting thrombin, inhibiting the hyperproduction of airway exudates, and inducing endogenous interferon."],"journal":"Int J Antimicrob Agents","authors":["LuoLiu, PanDong","Li, Juan"],"date":"2020-04-27T11:00:00Z","year":2020,"_id":"32335281","week":"202018|Apr 27 - May 03","doi":"10.1016/j.ijantimicag.2020.105995","keywords":["covid-19","sars-cov-2","glycyrrhizin"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1665172301917716480,"score":119.02918},{"pmid":32323646,"title":"Chloroquine and Hydroxychloroquine for the Prevention or Treatment of Novel Coronavirus Disease (COVID-19) in Africa: Caution for Inappropriate Off-Label Use in Healthcare Settings.","text":["Chloroquine and Hydroxychloroquine for the Prevention or Treatment of Novel Coronavirus Disease (COVID-19) in Africa: Caution for Inappropriate Off-Label Use in Healthcare Settings.","The novel severe acute respiratory syndrome-coronavirus-2 pandemic has spread to Africa, where nearly all countries have reported laboratory-confirmed cases of novel coronavirus disease (COVID-19). Although there are ongoing clinical trials of repurposed and investigational antiviral and immune-based therapies, there are as yet no scientifically proven, clinically effective pharmacological treatments for COVID-19. Among the repurposed drugs, the commonly used antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) have become the focus of global scientific, media, and political attention despite a lack of randomized clinical trials supporting their efficacy. Chloroquine has been used worldwide for about 75 years and is listed by the WHO as an essential medicine to treat malaria. Hydroxychloroquine is mainly used as a therapy for autoimmune diseases. However, the efficacy and safety of CQ/HCQ for the treatment of COVID-19 remains to be defined. Indiscriminate promotion and widespread use of CQ/HCQ have led to extensive shortages, self-treatment, and fatal overdoses. Shortages and increased market prices leave all countries vulnerable to substandard and falsified medical products, and safety issues are especially concerning for Africa because of its healthcare system limitations. Much needed in Africa is a cross-continental collaborative network for coordinated production, distribution, and post-marketing surveillance aligned to low-cost distribution of any approved COVID-19 drug; this would ideally be piggybacked on existing global aid efforts. Meanwhile, African countries should strongly consider implementing prescription monitoring schemes to ensure that any off-label CQ/HCQ use is appropriate and beneficial during this pandemic.","Am J Trop Med Hyg","Abena, Pascale M","Decloedt, Eric H","Bottieau, Emmanuel","Suleman, Fatima","Adejumo, Prisca","Sam-Agudu, Nadia A","Muyembe TamFum, Jean-Jacques","Seydi, Moussa","Eholie, Serge P","Mills, Edward J","Kallay, Oscar","Zumla, Alimuddin","Nachega, Jean B","32323646"],"abstract":["The novel severe acute respiratory syndrome-coronavirus-2 pandemic has spread to Africa, where nearly all countries have reported laboratory-confirmed cases of novel coronavirus disease (COVID-19). Although there are ongoing clinical trials of repurposed and investigational antiviral and immune-based therapies, there are as yet no scientifically proven, clinically effective pharmacological treatments for COVID-19. Among the repurposed drugs, the commonly used antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) have become the focus of global scientific, media, and political attention despite a lack of randomized clinical trials supporting their efficacy. Chloroquine has been used worldwide for about 75 years and is listed by the WHO as an essential medicine to treat malaria. Hydroxychloroquine is mainly used as a therapy for autoimmune diseases. However, the efficacy and safety of CQ/HCQ for the treatment of COVID-19 remains to be defined. Indiscriminate promotion and widespread use of CQ/HCQ have led to extensive shortages, self-treatment, and fatal overdoses. Shortages and increased market prices leave all countries vulnerable to substandard and falsified medical products, and safety issues are especially concerning for Africa because of its healthcare system limitations. Much needed in Africa is a cross-continental collaborative network for coordinated production, distribution, and post-marketing surveillance aligned to low-cost distribution of any approved COVID-19 drug; this would ideally be piggybacked on existing global aid efforts. Meanwhile, African countries should strongly consider implementing prescription monitoring schemes to ensure that any off-label CQ/HCQ use is appropriate and beneficial during this pandemic."],"journal":"Am J Trop Med Hyg","authors":["Abena, Pascale M","Decloedt, Eric H","Bottieau, Emmanuel","Suleman, Fatima","Adejumo, Prisca","Sam-Agudu, Nadia A","Muyembe TamFum, Jean-Jacques","Seydi, Moussa","Eholie, Serge P","Mills, Edward J","Kallay, Oscar","Zumla, Alimuddin","Nachega, Jean B"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32323646","week":"202017|Apr 20 - Apr 26","doi":"10.4269/ajtmh.20-0290","source":"PubMed","topics":["Treatment","Prevention"],"weight":1,"e_drugs":["Hydroxychloroquine","Chloroquine"],"_version_":1664895932725985280,"score":118.005005},{"pmid":32117569,"pmcid":"PMC7029759","title":"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.","text":["Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China.","A novel coronavirus (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV infection. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon infection, despite an urgent need to find options to help these patients and preclude potential death. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the virus may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, angiotensin-converting enzyme 2 (ACE2), fused to an immunoglobulin Fc domain, providing a neutralizing antibody with maximal breath to avoid any viral escape, while also helping to recruit the immune system to build lasting immunity. The sequence of the ACE2-Fc protein is provided to investigators, allowing its possible use in recombinant protein expression systems to start producing drug today to treat patients under compassionate use, while formal clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s).","F1000Res","Kruse, Robert L","32117569"],"abstract":["A novel coronavirus (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV infection. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon infection, despite an urgent need to find options to help these patients and preclude potential death. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the virus may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, angiotensin-converting enzyme 2 (ACE2), fused to an immunoglobulin Fc domain, providing a neutralizing antibody with maximal breath to avoid any viral escape, while also helping to recruit the immune system to build lasting immunity. The sequence of the ACE2-Fc protein is provided to investigators, allowing its possible use in recombinant protein expression systems to start producing drug today to treat patients under compassionate use, while formal clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s)."],"journal":"F1000Res","authors":["Kruse, Robert L"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32117569","week":"202010|Mar 02 - Mar 08","doi":"10.12688/f1000research.22211.2","keywords":["2019-ncov","ace2","wuhan","coronavirus","neutralizing antibody","outbreak"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Oligonucleotides"],"_version_":1664640875055022081,"score":113.46272}]}